Literature DB >> 23856784

Characterization of binding of raltegravir to plasma proteins.

Caroline Barau1, Valérie Furlan, Yazdan Yazdanpanah, Catherine Fagard, Jean-Michel Molina, Anne-Marie Taburet, Aurélie Barrail-Tran.   

Abstract

The objective of this study was to characterize raltegravir (RAL) binding to albumin and alpha-1-acid glycoprotein (AAG). Unbound and bound RAL were separated by ultrafiltration. The association constant (Ka) was estimated by a graphical method. In HIV-infected patients, the average plasma protein binding is 76%. RAL did not bind to AAG but bound to nonsaturable, low-affinity albumin sites with an n (number of sites) · Ka product of 9.8 × 10(2) liters/mol. A pH increase of 0.2 U led to a 2% increase in the bound fraction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23856784      PMCID: PMC3811458          DOI: 10.1128/AAC.00625-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Antiretroviral drug concentrations in semen of HIV-1 infected men.

Authors:  S Taylor; A S Pereira
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

2.  A structural transformation in bovine and human plasma albumins in alkaline solution as revealed by rotatory dispersion studies.

Authors:  W J LEONARD; K K VIJAI; J F FOSTER
Journal:  J Biol Chem       Date:  1963-06       Impact factor: 5.157

3.  The pH dependency of the binding of drugs to plasma proteins in man.

Authors:  Peter H Hinderling; Dieter Hartmann
Journal:  Ther Drug Monit       Date:  2005-02       Impact factor: 3.681

4.  Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs.

Authors:  A Viani; G Rizzo; M Carrai; G M Pacifici
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-04

Review 5.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

6.  Evidence for the fatty acid-induced heterogeneity of the N and B conformations of human serum albumin.

Authors:  J H Dröge; L H Janssen; J Wilting
Journal:  Biochem Pharmacol       Date:  1985-09-15       Impact factor: 5.858

7.  Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein.

Authors:  S Urien; E Albengres; R Zini; J P Tillement
Journal:  Biochem Pharmacol       Date:  1982-11-15       Impact factor: 5.858

8.  The binding of HIV-1 protease inhibitors to human serum proteins.

Authors:  Arne Schön; Maria del Mar Ingaramo; Ernesto Freire
Journal:  Biophys Chem       Date:  2003-09       Impact factor: 2.352

9.  pH homeostasis in human lymphocytes: modulation by ions and mitogen.

Authors:  C Deutsch; J S Taylor; M Price
Journal:  J Cell Biol       Date:  1984-03       Impact factor: 10.539

10.  The effect of albumin conformation on the binding of warfarin to human serum albumin. The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis.

Authors:  J Wilting; W F van der Giesen; L H Janssen; M M Weideman; M Otagiri; J H Perrin
Journal:  J Biol Chem       Date:  1980-04-10       Impact factor: 5.157

View more
  6 in total

1.  Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.

Authors:  Yi Zheng; Déborah Hirt; Sandrine Delmas; Gabrielle Lui; Sihem Benaboud; Jerome Lechedanec; Jean-Marc Tréluyer; Camille Chenevier-Gobeaux; Elisa Arezes; Ambre Gelley; Imane Amri; Saïk Urien; Naïm Bouazza; Frantz Foissac; Josiane Warszawski; Jade Ghosn
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity.

Authors:  Lauren Kirkwood-Johnson; Nana Katayama; Yusuke Marikawa
Journal:  Toxicol Sci       Date:  2021-11-24       Impact factor: 4.849

3.  Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.

Authors:  Thibaut Gelé; Hélène Gouget; Valérie Furlan; Pierre-Hadrien Becker; Anne-Marie Taburet; Olivier Lambotte; Aurélie Barrail-Tran
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 4.  Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.

Authors:  Anthony T Podany; Kimberly K Scarsi; Courtney V Fletcher
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

Review 5.  Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.

Authors:  Ruben van der Galiën; Rob Ter Heine; Rick Greupink; Stein J Schalkwijk; Antonius E van Herwaarden; Angela Colbers; David M Burger
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

Review 6.  Pharmacokinetic drug interactions of integrase strand transfer inhibitors.

Authors:  Chi-Hua Lu; Edward M Bednarczyk; Linda M Catanzaro; Alyssa Shon; Jia-Chen Xu; Qing Ma
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.